Canada Markets close in 3 hrs 51 mins

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3050+0.0050 (+1.67%)
As of 11:25AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.3000
Open0.3010
BidN/A x N/A
AskN/A x N/A
Day's Range0.2990 - 0.3050
52 Week Range0.0459 - 0.6200
Volume13,885
Avg. Volume359,356
Market Cap23.442M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

    BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T cell diagnostic for detecting an immune response to SARS-CoV-2, by filing an international patent application through the Patent Cooperation Treaty ("PCT") for broad geographic market coverage outside the US. Although CoviDTH diagnostic results are intended to be visually interpreted by a trained technician or healthcare provider

  • Baystreet

    Stocks in play: BioVaxys Technology Corp.

    Announced today that it has filed with the United States Patent & Trademark Office a provisional patent ...

  • CNW Group

    BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

    BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of Coronaviruses that includes SARS-CoV-2, which causes Covid-19.